Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Reliable Life Defense. Each vial contains: Each vial contains: Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume.

Similar presentations


Presentation on theme: "The Reliable Life Defense. Each vial contains: Each vial contains: Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume."— Presentation transcript:

1 The Reliable Life Defense

2 Each vial contains: Each vial contains: Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume of 1 ml. Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume of 1 ml.

3 Filgrastim Filgrastim is a glycoprotein which acts on hematopoietic cells in bone marrow, stimulating their proliferation & differentiation to neutrophils. Filgrastim Filgrastim accelerates improvement of neutrophils count & their functional activation (enhanced phagocytic ability) Filgrastim Filgrastim is a glycoprotein which acts on hematopoietic cells in bone marrow, stimulating their proliferation & differentiation to neutrophils. Filgrastim Filgrastim accelerates improvement of neutrophils count & their functional activation (enhanced phagocytic ability)

4 To reduce the incidence, severity & duration of neutropenia associated with chemotherapy (Interferon) Cancer patients receiving myelosuppressive chemotherapy Patients with acute myeloid leukemia receiving induction Chemotherapy Patients with severe chronic neutropenia

5 Cancer patients undergoing peripheral Blood Progenitor Cell Collection and Therapy Cancer patients receiving bone marrow transplant Patients with acute myeloid leukemia receiving induction Chemotherapy Patients with severe chronic neutropenia

6 Filgrastim dose: 4 to 8 mcg/kg for up to 14 consecutive days following each cycle of chemotherapy Duhrsen U Villeval JL Boyd J et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-2081. Cancer Patients Receiving Myelo- suppressive Chemotherapy

7 Dosage & Administration is individualized according to patients clinical course & average neutrophil count Filgrastim Filgrastim should be given once daily by I.V. or S.C. injection (after 24 – 48 hours of administration of chemotherapy or radiotherapy)

8 Cancer patients receiving myelosuppressive chemotherapy: Cancer patients receiving myelosuppressive chemotherapy: 5 µg/kg body weight /day as a single daily dose by S.C. injection or I.V. infusion over 15 – 30 minutes

9 Patients with severe chronic neutropenia: Patients with severe chronic neutropenia: Initial dose Congenital: 6µg/kg body weight twice daily by S.C. injection Idiopathic: 5µg/kg body weight /day as a single S.C. injection

10 Cancer patients receiving bone marrow transplant: Cancer patients receiving bone marrow transplant: 10 µg/kg body weight /day as I.V. infusion for 4 – 24 hours

11 Cancer patients undergoing peripheral Blood Progenitor Cell Collection and Therapy: Cancer patients undergoing peripheral Blood Progenitor Cell Collection and Therapy: 10 µg/kg body weight /day either as a bolus or a continuous infusion at least 4 days before the first procedure for 6 – 7 days, on day 5,6,7. Dose modification in case of reaching WBCs count exceeding 100,000 / mm 3

12 Filgrastim Filgrastim is kept in refrigerator at 2 – 8 o C Filgrastim Filgrastim can be kept at room temp. for a maximum of 24 hours Filgrastim Filgrastim vial should not be shacked Filgrastim Filgrastim vial should not be reused, the unused portion must be discarded

13 1 vial (1 ml) … 350 L E. 1 vial (1 ml) … 350 L E.

14 The Reliable Life Defense


Download ppt "The Reliable Life Defense. Each vial contains: Each vial contains: Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume."

Similar presentations


Ads by Google